Our Response to COVID-19

Hide Quick View button
Product Navigation Left Arrow 1OF Product Navigation Right Arrow
Observational Paper

The COVID-19 pandemic continues to challenge the way health care providers and manufacturers approach critical care in this country. This observational paper captures the trends in the clinical setting, the decision-making process behind treatment strategies, and Baxter products and services used to care for critically ill patients.

Supply Confidence

The future will bring new challenges as we deal with continued pandemic surges, supply challenges and the need to resume normal operations as quickly as possible. See how Baxter is ensuring access to our products to provide you with reliable, consistent product supply.

DoseEdge Pharmacy Workflow Manager

The DoseEdge Pharmacy Workflow Manager System helps preserve cleanroom resources by reducing person to person interactions and optimizing the use of PPE.

Starling Fluid Management Monitoring System

The Starling Fluid Management Monitoring System can help manage patient fluids during the COVID-19 pandemic. Non-invasive, accurate and easy to deploy, the Starling can support you by providing necessary hemodynamic patient information at the bedside, providing you with confidence in optimizing care for your patients.

 

Q-NRG+ Metabolic Monitor
  • Fast: around 10-15 minutes to run a test
  • Intuitive: Real-time, user friendly dashboard with flexibility to use in intubated and spontaneously breathing patients.

INDICATIONS FOR USE

The Q-NRG+ portable Metabolic Monitors are indicated for the measurement of Resting Energy Expenditure (REE) for spontaneously breathing and ventilated patients, within the following populations:

  • Spontaneously breathing subjects >15 kg (33 lb) when using a canopy .
    • Spontaneously breathing subjects age >6 yrs and >10 kg (22 lb) when using a face mask.
    • Ventilated subjects age >10 yrs and >10 kg (22 lb).

The Q-NRG+ Portable Metabolic Monitors are intended to be used in professional healthcare facilities only.

Warnings

This device measures clinical parameters used to aid diagnosis and it is intended only as an adjunct device in patient assessment. In case of disturbing conditions, the shutdown is allowed because the safety of the device towards patients and operators is not affected, since the final evaluation is performed on the outcome data measured during a complete test. No modification of this device is allowed.

Precautions/Contraindications

Carefully re-check ventilator functionality after connection of the parts. Make sure that the patients cuff pressure is high enough to avoid
air leakage. Manipulation of the ventilator circuit may cause leaks that may lower alveolar ventilation. For more information please refer
to User’s Manual.

Rx Only: For safe and proper use of products mentioned herein, please refer to the Instructions for Use or Operator’s Manual.

Clinimix (amino acids in dextrose) Injections

Clinimix sulfite-free (amino acid in dextrose) Injections

Clinimix E sulfite-free (amino acid with electrolytes in dextrose and calcium) Injections

Clinimix injections are an alternative to compounding and may help to conserve Personal Protective Equipment (PPE).

INDICATIONS AND IMPORTANT RISK INFORMATION FOR CLINIMIX

Indications

CLINIMIX (amino acids in dextrose) Injections and CLINIMIX E (amino acids with electrolytes in dextrose with calcium) Injections are indicated as a source of calories and protein (and electrolytes for CLINIMIX E) for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX and CLINIMIX E may be used to treat negative nitrogen balance in patients.

Important Risk Information

  • CLINIMIX and CLINIMIX E Injections are contraindicated in patients with known hypersensitivity to one or more amino acids or dextrose; in patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications; and in patients with pulmonary edema or acidosis due to low cardiac output. In addition, CLINIMIX E is contraindicated in neonates (less than 28 days of age) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate’s bloodstream.
  • Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. Excess addition of calcium and phopshate increases the risk of the formation of calcium phosphate precipitates. The solution should be inspected for precipitates before admixing, after admixing, and again before administration. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.
  • Precipitation of ceftriaxone-calcium can occur when ceftriaxone is mixed with CLINIMIX E, in the same intravenous administration line. Do not administer ceftriaxone simultaneously with CLINIMIX E via a Y-site.
  • Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop.
  • Monitor for signs and symptoms of early infections.
  • Refeeding severely undernourished patients may result in refeeding syndrome. Thiamine deficiency and fluid retention may also develop. Monitor severely undernourished patients and slowly increase nutrient intakes.
  • CLINIMIX and CLINIMIX E solutions containing more than 5% dextrose have an osmolarity of ≥ 900 mOsm/L and must be infused through a central catheter.
  • CLINIMIX and CLINIMIX E contain no more than 25 mcg/L of aluminum which may reach toxic levels with prolonged administration in patients with renal impairment. Preterm infants are at greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum. Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
  • Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants. If CLINIMIX and CLINIMIX E treated patients develop liver test abnormalities consider discontinuation or dosage reduction.
  • Use CLINIMIX and CLINIMIX E with caution in patients with cardiac insufficiency or renal impairment due to increased risk of electrolyte and fluid volume imbalance.
  • Monitor renal and liver function parameters, ammonia levels, fluid and electrolyte status, serum osmolarity, blood glucose, blood count and coagulation parameters throughout treatment. In situations of severely elevated electrolyte levels, stop CLINIMIX and CLINIMIX E until levels have been corrected.
  • Adverse reactions include diuresis, extravasation, glycosuria, hyperglycemia, and hyperosmolar coma.

Please click here for full Prescribing Information for Clinimix.
Please click 
here for full Prescribing Information for Clinimix E.

 

U.S. Medical Information

US Medical Information

Baxter Medical Information works to inform and educate healthcare professionals and patients about our products by providing clinical and scientific information to help support clinical decisions.

Login or Register here for US Medical Information Online, or go to https://Medinfo.baxter.com

 

US Medical Information Online is a self-service portal intended for Healthcare Professionals or employees of a healthcare institutions to search and download frequently requested product information.

For your convenience US Medical Information representatives are also available by email and phone.

Email[email protected]

Hospital Products Phone: 1-800-933-0303

This experience is designed for larger screens.

To experience this site as intended please make your browser window larger or view it on a tablet, laptop, or desktop screen.

Proceed on smaller screen